We all know Genentech lic’ed this drug out as it did not fit it’s stable and focus - but found it incredibly interesting... so much so rather than leave it on the shelf we were chosen to steward its trials etc
and thats what James said in interview “we look for interesting drugs that don’t fit their current owners existing focus or stable” paraphrasing but essentially that statement - the interview was posted here days ago on HC... literally days ago.
so by pointing out a 240 billion company let it go - that was a strategic decision on company direction and strategic planning it’s size is irrelevant and why it didn’t want to continue with it internally well understood.
regarding...
Cash required and control over over trials
you have said this for three years - and yet we have a drug that works stated by the company and its in its final trial for fda approval and with money in the bank - new GBM Agile is the cheapest quickest method of trial construction to date.
licence agreements balance sheet etc
yes our licences are all in order and held by us and again 6 mill in the bank which is around what we always have in the bank - when running a lean agile funding machine and it’s worked for 3.5 years as you say.
Immunotherapy and others possible breakthroughs
all existing treatments in all categories of medicine have new treatments in their category just around the corner yet it takes 15-20 years to bring drugs online - it’s getting quicker yes but we know the landscape and there’s nothing close to us out there and yes we are in the last trial stage for FDA approval
How difficult and expensive it will to penetrate the market with a new drug on PFS -
Our company is called Kazia and it focuses to mid stage trials we partner for commercialisation - with FDA approval and a working beneficial drug partners will queue up - we know they are already in discussions as they have previously released... it’s not a mater of if or not it’s a matter of the deal.
if successful TMZ has been around for decades and used on varying patients over years etc
as will we be - we are in the quickest cheapest trial to date and are collecting data for FDA approval - we will be around for years in commercialisation as well - company values the opportunity at 1.5 billion
Read the company half yearly report we have a drug that works
We are very late in the game with Paxalisib as they state.
